Status:
UNKNOWN
Preemptive and Precise Intervention for CKD-SHPT
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Hyperparathyroidism; Secondary, Renal
Eligibility:
All Genders
18+ years
Brief Summary
Through multi-center randomized controlled trial studies on preemptive surgical intervention in patients with chronic kidney disease (CKD) - secondary hyperparathyroidism (SHPT), to precisely evaluate...
Eligibility Criteria
Inclusion
- 1\) Chronic Kidney Disease Stage 3-5d patients aged ≥18 years;
- 2\) The diagnosis is consistent with CKD-metabolic bone disease and SHPT after evaluation by a kidney specialist;
- 3\) Sustained blood immunoreactive parathyroid hormone level of \> 300ng/ml, and had received drug treatment;
- 4\) Persistent hypercalcemia and/or hyperphosphatemia that is not responding to medication;
- 5\) Imaging suggested evidence of at least one parathyroid nodular hyperplasia;
- 6\) Signed the informed consent.
Exclusion
- 1\) Age \<18 years old;
- 2\) Patients with dialysis duration \< 3 months, or with other unstable dialysis state;
- 3\) Kidney transplant patients;
- 4\) Who is considered inappropriate to participate in this study after evaluation by the supervising physician.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04523974
Start Date
October 1 2020
End Date
December 31 2022
Last Update
August 24 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.